Telesis Bio, Inc.

Equities

TBIO

US1920031010

Advanced Medical Equipment & Technology

Market Closed - Nasdaq 04:30:00 2024-04-22 pm EDT 5-day change 1st Jan Change
0.3152 USD +2.01% Intraday chart for Telesis Bio, Inc. -16.55% -21.00%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Telesis Bio, Inc. Announces Appointment of Eric Esser to the Board of Directors CI
Telesis Bio Inc. Announces Strategic Focus on Game-Changing Gibson Sola Enzymatic DNA Synthesis Platform and BioXp mRNA Solutions CI
Telesis Bio, Inc. Announces Chief Executive Officer Changes CI
Earnings Flash (TBIO) TELESIS BIO Reports Q4 Revenue $7M MT
Telesis Bio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Telesis Bio, Inc. Reports Impairment Charges for the Fourth Quarter Ended December 31, 2023 CI
Telesis Bio, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Earnings Flash (TBIO) TELESIS BIO Posts Q3 Revenue $5.6M, vs. Street Est of $7.4M MT
Telesis Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Telesis Bio, Inc. Provides Earnings Guidance for 2023 CI
Telesis Bio, Inc. Announces Default of 2022 Term Loan Agreement CI
Telesis Bio, Inc. Announces Board Changes CI
Telesis Bio Names William Kullback as CFO MT
Telesis Bio Inc. Appoints William J. Kullback Chief Financial Officer CI
North American Morning Briefing : Stock Futures -2- DJ
Telesis Bio Downgraded by KeyBanc Over 'Tepid' Biopharma Spending, 'Significant Dilution' MT
KeyBanc Downgrades Telesis Bio to Sector Weight From Overweight, Cites 'Limited Top-Line Visibility' Amid 'Tepid Biopharma Spending Environment' MT
Transcript : Telesis Bio, Inc., Q2 2023 Earnings Call, Aug 10, 2023
Earnings Flash (TBIO) TELESIS BIO Posts Q2 Revenue $8.7M, vs. Street Est of $8.6M MT
Telesis Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Top Premarket Gainers MT
Telesis Bio, Inc. Appoints Paul Meister as Director CI
Telesis Bio, Inc. announced that it has received $28 million in funding from Novalis Capital Partners LLC, Northpond Ventures, LLC, BroadOak Capital Partners LLC, Investment Arm and another investor CI
Telesis Bio Secures $28 Million Preferred Equity Financing MT
Telesis Bio, Inc. announced that it expects to receive $28 million in funding from Novalis Capital Partners LLC, Northpond Ventures, LLC, BroadOak Capital Partners LLC, Investment Arm and another investor CI
Chart Telesis Bio, Inc.
More charts
Telesis Bio Inc. is a provider of ribonucleic acid (RNA) and deoxyribonucleic acid (DNA) solutions. The Company provides automated multi-omic and synthetic biology solutions focused on providing applications to enable researchers to rapidly and reproducibly build or write high-quality synthetic DNA and messenger Ribonucleic Acid (mRNA) and short oligonucleotides that are ready to use in many downstream synthetic biology enabled markets. Its BioXp system consolidates, automates, and optimizes the entire synthesis, cloning and amplification workflow. Its on-market and its planned solutions include BioXp 3250 system, BioXp 9600 system, BioXp portal, BioXp De Novo kits, BioXp Select kits, BioXp Next Generation Sequencing kits, Benchtop reagents and Custom Gibson Short Oligo Ligation Assembly (SOLA) enzymatic DNA synthesis (EDS) solutions. BioXp Select kits offer customers the ability to use non-Telesis Bio DNA while using the BioXp system to perform synthetic biology workflow applications.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.3152
Average target price
-
Consensus
  1. Stock Market
  2. Equities
  3. TBIO Stock
  4. News Telesis Bio, Inc.
  5. Codex DNA : Shares Gain in Stock Market Debut